Skip to content

Boostability of One priming dose intramuscular Rabies vaccine especially in Senior age groups

Boostability of One priming dose intramuscular Rabies vaccine especially in Senior age groups

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619000946112
Acronym
BORS
Enrollment
103
Registered
2019-07-05
Start date
2020-01-17
Completion date
2020-10-02
Last updated
2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Rabies is a fatal disease, present in most countries outside Australia, so poses a risk to Australian travellers. Although deaths in travellers are rare (60 reported cases 1990 – 2012 ), rabies risk exposures are relatively common (2-13/1000 travellers per month). In travellers who are aware the horrors of this untreatable disease, a potential rabies exposure can be stressful, and cause major disruption to travel plans in the quest for appropriate treatment. Pre-exposure rabies vaccination (PrEP) simplifies the treatment of animal exposures if they occur during travel. The standard recommendations for rabies PrEP is to give 2-3 doses of vaccine prior to departure. The Australian guidelines recommend PrEP - one dose of Rabies vaccine given on day 0,7,and 21-28. Many travellers are leaving at short notice and do not have time to complete this pre departure rabies vaccine course. Recent research has suggested that two doses or even one dose may be sufficient to prime the immune system, and simplify the post exposure treatment of at risk animal exposures. Much of the research in the past has be done on young soldiers. There is very limited research in persons over the age of 50 years to confirm that persons in this age group mount an adequate immune response to lower doses of rabies vaccine.

Interventions

Intramuscular (deltoid) administration of 0.5ml of Verorab (containing not less than 2.5 international units of inactivated Wistar rabies virus strain per 0.5ml) at days 0, 60, and 63

Sponsors

Luis Furuya-Kanamori
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Primary purpose
Prevention

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. No prior history of rabies vaccination 2. Able to give written Informed Consent and sign consent after all aspects of the protocol have been explained 3. Subject must agree to participate in three doses of vaccine, three to four blood tests and two questionnaires including the planned follow-up telephone review

Exclusion criteria

1. Taking medications that impair the normal functioning of the immune system 2. Pregnancy or planning pregnancy 3. Travelling to areas of high risk for rabies where an unusual pre-exposure prophylaxis schedule may cause difficulty in the event of an animal exposure that requires post-exposure prophylaxis

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 15, 2026